Long-term risk of new-onset arrhythmia in ST-segment elevation myocardial infarction according to revascularization

Anna F Thomsen1, Christian Jøns1, Reza Jabbari1

  • 1Department of Cardiology, Rigshospitalet University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Insights

Incomplete revascularization after ST-segment elevation myocardial infarction (STEMI) increases long-term arrhythmia risk. This study found incomplete revascularization (ICR) is linked to higher rates of new-onset arrhythmia and mortality compared to complete revascularization (CR).

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Electrophysiology

Background:

  • Complete revascularization (CR) is known to reduce adverse cardiovascular events post-ST-segment elevation myocardial infarction (STEMI).
  • The long-term impact of revascularization status on arrhythmia development after STEMI remains incompletely understood.

Purpose of the Study:

  • To investigate the association between incomplete revascularization (ICR) versus CR and the long-term risk of new-onset arrhythmia in STEMI patients.
  • To evaluate the impact of revascularization status on specific arrhythmia types and all-cause mortality.

Main Methods:

  • Retrospective analysis of 5103 STEMI patients treated with primary percutaneous coronary intervention (PPCI) from 2009-2016.
  • Utilized Danish administrative registries to assess outcomes, defining new-onset arrhythmia as a composite of atrial fibrillation/flutter, heart blocks, ventricular tachycardia/fibrillation, or cardiac arrest occurring >7 days post-PPCI.
  • Compared outcomes between patients with CR (n=4009) and ICR (n=1094) using adjusted hazard ratios.

Main Results:

  • ICR was significantly associated with an increased long-term risk of new-onset arrhythmia compared to CR (HR, 1.33; 95% CI, 1.07-1.66; P=0.01).
  • Specific findings included a higher risk of atrial fibrillation (HR, 1.29; P=0.05), ventricular tachycardia/cardiac arrest (HR, 1.77; P=0.02), and all-cause mortality (HR, 1.27; P=0.01) in the ICR group.
  • The study included a large cohort with a median age of 62.0 years, 76% of whom were men.

Conclusions:

  • In STEMI patients treated with PPCI, incomplete revascularization is linked to a greater long-term risk of developing new-onset arrhythmia.
  • ICR is also associated with an increased risk of all-cause mortality in the long-term post-STEMI period.
  • These findings underscore the importance of achieving complete revascularization for improved long-term outcomes in STEMI patients.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
56
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
34
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13